Innovative approach enables PPD to deploy
studies utilizing Science 37's SaaS Platform
PPD, Inc. (Nasdaq: PPD), a leading global contract research
organization (CRO), and Science 37, developer of the Decentralized
Clinical Trial Operating System™ (DCT OS), today announced an
innovative collaboration in which PPD will be fully enabled to
design, build, test, implement and execute digital trials using
Science 37's DCT SaaS-based technology platform.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210427005680/en/
The extended arrangement, which is a result of their successful
two-year collaboration under Science 37’s CRO Certified program,
will enable PPD® Digital to utilize Science 37's configurable,
SaaS-based DCT technology platform to design and implement Remote
eConsent, eCOA, eSource and fully decentralized trials, which will
enhance the company’s efficiency and effectiveness in delivering
studies for customers.
"Our success with Science 37 has positioned us well to implement
and incorporate its technology platform into our clinical trial
services model, which is on course with our efforts to maintain a
leadership position in the global transition toward decentralized
clinical trials," said Niklas Morton, senior vice president, PPD
Digital. "Our overall DCT strategy is to offer customers more trial
delivery options, particularly in a stepwise fashion where the
customer can experience both traditional and digital approaches to
sites and patients in the same study. Through our evolving
collaboration, we will be able to use the Science 37 platform to
provide our customers with a best-in-class service and delivery
model."
PPD Digital provides flexible trial solutions across the
decentralized spectrum to increase patient access and improve the
patient experience, resulting in time efficiencies and data quality
enhancements that can help speed development timelines. These
services significantly reduce the burden for patients, mainly
through fewer site visits, while providing clients with greater
geographic reach through reduced reliance on sites, more timely
access to data, improved quality and consistency, and better
patient engagement.
“Science 37 intends to be the operating system to enable all
decentralized clinical trials,” said Steve Geffon, chief commercial
officer of Science 37. “By enabling PPD Digital to utilize our
innovative platform, we’re able to extend our reach and enable
decentralization on more trials than ever before. Our new
SaaS-based technology makes it easy to deploy Remote eConsent,
eCOA, eSource and fully decentralized trials, even when it’s not
part of the complete Science 37 DCT Operating System, which
includes patient communities, telemedicine investigators, mobile
nurses, remote coordinators and connected devices.”
Last month, PPD was recognized for industry leadership in
digital and decentralized clinical trial solutions by Information
Services Group (ISG), a leading global technology research and
advisory firm. ISG named PPD an ISG Provider Lens Leader for the
CRO's digital transformation services, specifically PPD's clinical
development and patient engagement solutions.
In 2019, PPD led the series D financing round for Science 37 and
created a partnership to offer virtual sites that can augment
traditional brick-and-mortar sites. This early investment has
enabled PPD to solution protocol development and protocol
adjustment processes to facilitate DCT design flexibility; optimize
the study startup process and workflow to ensure faster site
activation timelines; leverage the PPD business Accelerated
Enrollment Solutions to maximize patient recruitment potential; and
integrate data acquisition at sites with PPD's data management and
Preclarus® platform to ensure real-time data access across all
sites.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory, and
lifecycle management services. Our customers include
pharmaceutical, biotechnology, medical device, academic, and
government organizations. With offices in 47 countries and more
than 27,000 professionals worldwide, PPD applies innovative
technologies, therapeutic expertise, and a firm commitment to
quality to help customers bend the cost and time curve of drug
development and optimize value in delivering life-changing
therapies to improve health. For more information, visit
www.ppd.com.
About Science 37
Science 37 enables universal access to clinical research—making
it easier for patients and providers to participate and
accelerating the development of new and innovative treatments that
impact patient lives. With the Decentralized Clinical Trial
Operating System™ (DCT OS), we enable workflow orchestration,
evidence generation, and data harmonization on a unified, seamless
platform—configurable to enable any study and fused with our
expansive networks of telemedicine investigators, mobile nurses,
remote coordinators, patient communities and connected devices. For
more information, visit https://www.science37.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the planned
acquisition of PPD by Thermo Fisher Scientific Inc.; and other
factors disclosed under the “Risk Factors” section in our periodic
reports filed with the Securities and Exchange Commission (SEC),
including our latest Annual Report on Form 10-K, which is available
on our website at https://investors.ppd.com or the SEC’s website at
www.sec.gov. We assume no obligation and disclaim any duty to
revise or update any forward-looking statements, or make any new
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005680/en/
PPD Contacts Media: Randy Buckwalter +1 919 456 4425
media@ppd.com
Investors: Tracy Krumme +1 910 558 4186 investors@ppd.com
Science 37 Contact Margie Kooman +1 984 377 3737
pr@science37.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jun 2023 to Jun 2024